Therapeutic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure with preserved ejection fraction: From outcome improvement to potentially favourable influences on atrial fibrillation burden, atrial fibrillation progression and atrial cardiomyopathy

MeSH terms

• Atrial Fibrillation* / complications
• Atrial Fibrillation* / drug therapy
• Cardiomyopathies*
• Glucose
• Heart Failure* / complications
• Heart Failure* / drug therapy
• Humans
• Sodium
• Stroke Volume